No Data
No Data
Is Novo Nordisk A/S (NVO) the Most Promising Biotech Stock According to Hedge Funds?
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Eli Lilly's Zepbound to Undergo First-of-its-kind Study on Economic Impact
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Hims +6% Monday After FDA Said it Might Halt Hims Weight Loss Drug Sales Friday
Amgen's stock price has dropped, analysts warn that the speculation on weight loss drugs has already been digested by the market.
Amgen Inc.'s stocks fell on Monday after an analyst no longer holds a bullish view on this biotechnology giant, citing concerns that investor optimism about a candidate obesity drug has been reflected in the stock price, with more downside risks than upside opportunities. Truist analyst Srikripa Devarakonda downgraded the stock from buy for the past 11 months to hold. However, she raised the target price from $320 to $333, but the new target price is only 1.4% higher than last Friday's closing price. The stock traded down 1.1% in pre-market trading, following a rise last Friday